ADAR1 Capital Management LLC Has $1.40 Million Position in Acelyrin, Inc. (NASDAQ:SLRN)

ADAR1 Capital Management LLC boosted its stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 731.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 444,967 shares of the company's stock after acquiring an additional 391,467 shares during the quarter. ADAR1 Capital Management LLC owned 0.44% of Acelyrin worth $1,397,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in shares of Acelyrin by 21.9% during the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock worth $163,000 after buying an additional 9,332 shares during the period. Virtu Financial LLC bought a new position in shares of Acelyrin during the 3rd quarter worth approximately $50,000. HighTower Advisors LLC acquired a new stake in shares of Acelyrin in the third quarter valued at approximately $50,000. Intech Investment Management LLC boosted its holdings in Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock worth $83,000 after purchasing an additional 11,040 shares during the last quarter. Finally, RPO LLC bought a new position in Acelyrin in the fourth quarter valued at $46,000. 87.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.60% of the stock is owned by company insiders.

Acelyrin Trading Up 3.7 %

NASDAQ:SLRN traded up $0.08 on Friday, hitting $2.23. The company's stock had a trading volume of 580,658 shares, compared to its average volume of 1,222,729. Acelyrin, Inc. has a one year low of $1.85 and a one year high of $7.25. The stock has a fifty day moving average of $2.43 and a two-hundred day moving average of $3.54. The firm has a market capitalization of $224.58 million, a P/E ratio of -0.91 and a beta of 1.12.

Acelyrin (NASDAQ:SLRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07. As a group, sell-side analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SLRN. Citigroup reduced their price objective on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. HC Wainwright lowered their price target on Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $9.60.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.